3 Pancreatic Cancer Forum

Transcription

1 3 Pancreatic Cancer Forum rd Milano, November 6th -7th, 2015 San Raffaele Congress Centre Chairmen of the Congress Dr. Michele Reni Ospedale San Raffaele, Milano, Italy Prof. Massimo Falconi Università Vita-Salute San Raffaele, Milano, Italy Ospedale San Raffaele, Milano, Italy Prof. Stefano Cascinu Università Politecnica delle Marche, Ancona, Italy Prof. Giampaolo Tortora Università degli Studi di Verona, Italy Organising Secretariat Acheloís Professional Congress Organiser Milano, Italy Phone Fax linda.isella@achelois.eu

2 SCIENTIFIC PROGRAMME Friday, November 6 th Welcome and introduction SESSION 1: BASIC RESEARCH IN PANCREATIC CANCER: SHIFTING EPIDEMIOLOGY AND BASIC SCIENCE ADVANCES Chairmen: N. Funel, M. Löhr, P. Maisonneuve Changing epidemiology of pancreatic cancer: Why is it still increasing? P. Maisonneuve Why is pancreatic cancer so difficult to detect? The challenge of early detection M. Löhr PANEL DISCUSSION Epidemiology and the difficulties with early detection in pancreatic cancer and the relevance to clinical practice P.G. Arcidiacono, N. Funel, M. Löhr, P. Maisonneuve Key advances in basic science New 3D-pancreatic cell culture system as a tool to evaluate human PDAC V. Corbo Carcinoma-associated fibroblast-derived CXCL12 in pancreatic tumour cell immune evasion (promise of plerixafor) L. Magiera Defective extrusion, due to reduced SP12 in pancreatic cancer may be involved in tumourigenesis, invasion and metastasis; potential role of FAK inhibitors J. Rosenblatt KEYNOTE LECTURE Why is pancreatic cancer so difficult to treat? The basic research challenges M. Hidalgo

3 PANEL DISCUSSION V. Corbo, M. Hidalgo, L. Magiera, J. Rosenblatt (including audience keypad voting on the pancreatic research challenges) Coffee break SESSION 2: BASIC RESEARCH IN PANCREATIC CANCER: IMMUNE ESCAPE MECHANISMS AND THE PROMISE OF IMMUNOTHERAPY Chairmen: L. Magiera, M.P. Protti, A. Scarpa How does pancreatic cancer avoid the immune system? M.P. Protti PANEL DISCUSSION The immunogenic potential of pancreatic cancer and the relevance to clinical practice M.P. Protti, A. Scarpa WORKSHOP A Group 1: Strategic immunotherapy/vaccine/checkpoint inhibitor workshop Coordinators: S. Cascinu, M.P. Protti Lunch Group 2: Early detection of pancreatic cancer Coordinators: P.G. Arcidiacono, M. Löhr SESSION 3: TRANSLATIONAL RESEARCH: GENOMICS AND THE STROMA Chairmen: A. Biankin, F. De Vita, R. Ramanathan Genomics update: can we translate the promise into clinical trials or daily practice soon? A. Biankin CUTTING THE HEDGE - Stroma: Friend or foe? Title to be defined R. Kalluri, The Multi-compartment effects of Hedgehog signaling in Pancreatic Cancer Stroma K.P. Olive

4 PANEL DISCUSSION Genomics and the stroma and the relevance to clinical practice A. Biankin, F. De Vita, R. Kalluri, K.P. Olive, R. Ramanathan Coffee break SESSION 4: TRANSLATIONAL RESEARCH: RESISTANCE AND STEM CELLS Chairmen: N. Silvestris, C. Swanton, G. Tortora Implications of intratumour heterogeneity for Drug Development C. Swanton The role of pancreatic stem cells and how to target them effectively P. Sancho PANEL DISCUSSION Key on mechanisms of treatment resistance and stem cells in PDAC and the relevance to clinical practice P. Sancho, N. Silvestris, C. Swanton, G. Tortora WORKSHOP B Group 1: utilizing genomics, epigenetic and molecular profiling in pancreatic cancer Coordinators: A. Biankin, G. Tortora Group 2: Biomarkers: issues and controversies Coordinators F. De Vita, D. Palmer Chairs summary and workshop feedback

5 Saturday, November 7 th Introduction of 2 nd Day Meeting SESSION 5: CLINICAL MANAGEMENT OF PANCREATIC CANCER: EARLY-STAGE AND LOCALLY ADVANCED DISEASE Chairmen: M.D. Chuong, M. Falconi, R. Ramanathan, G. Zamboni Neoadjuvant therapy update, issues and future direction M. Reni CASE STUDY DISCUSSION Optimal therapy in resectable disease M.D. Chuong, M. Milella, D. Palmer Introduced by M. Falconi CASE STUDY DISCUSSION Downsizing in borderline resectable disease G. Balzano, W. Scheithauer, A. Morganti Introduced by R. Ramanathan Pathological controversies and advances G. Zamboni Update on pathological controversies and advances after resection C. Doglioni Coffee break CASE STUDY DISCUSSION Unresectable disease: what are the options when surgery is no longer an option? M.D. Chuong, M. Ducreux Introduced by A. Morganti

6 SESSION 6: CLINICAL MANAGEMENT OF PANCREATIC CANCER: METASTATIC DISEASE Chairmen: G. Aprile, C. Bassi, S. Cascinu, A. Zerbi Optimal management of minimal metastatic disease: Role of local treatment M. Büchler Metastatic pancreatic cancer update P. Philip PANCREOS Registry A. Carrato PANEL DISCUSSION Metastatic disease G. Aprile, M. Büchler, S. Cascinu, P. Philip, A. Zerbi CASE STUDY DISCUSSION Optimal treatment in metastatic setting with keypad voting E. van Cutsem The European Cancer Patient Coalition initiatives A. Stunt Lunch CASE STUDY DISCUSSION Optimal treatment in metastatic setting with keypad voting T. Seufferlein Advancing the management of cancer cachexia: how do we improve patient outcomes? J. Arends PANEL DISCUSSION Advancing the management of cancer cachexia G. Aprile, S. Cascinu, A. Zerbi WORKSHOP C Group 1: Optimisation of supportive care Coordinators: G. Aprile, J. Arends

7 Coffee break Group 2: Innovation in therapy and management of patients with PDAC Coordinators: M. Ducreux, P.Corrie KEYNOTE LECTURE Precision, personalisation and the future of pancreatic cancer: where do we go from here? Development of a comprehensive clinical and research program in PC M. Moore Chairs summary and workshop feedback Departures